RANI News and Press, Rani Therapeutics Holdings Inc. From 02/05/24

2024-02-05 08:31:42 ET Chenghe Acquisition  ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies  ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...

2024-02-05 08:25:25 ET More on pre-market losers & stocks. Livent: Undervalued With Significant Upside Potential Livent: Wonderful Company Fairly Valued Livent And Albemarle: 2 Lithium Stocks To Buy Now Livent and Allkem shareholders approve merger of equ...

- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial that meets its primary endpoints – ...

- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data support the potential for the RaniPill platform to enable oral delivery of multiple obesity treatments - SAN JOSE, Calif., Dec. 14, ...

2023-12-08 12:45:17 ET Gainers: Intensity Therapeutics ( INTS ) +100% . MBIA ( MBI ) +74% . Conduit Pharmaceuticals ( CDT ) +47% . EF Hutton Acquisition Corp I ( EFHT ) +44% . Alx Oncology Holdings ( ALXO ) +35% . View ( VI...

2023-12-08 10:43:47 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Rani Therapeutics GAAP EPS of -$0.36 misses by $0.05 Canaccord believes Rani restructuring will help speed development For further details see: ...

2023-12-06 12:46:20 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Seeking Alpha’s Quant Rating on Rani Therapeutics Historical earnings data for Rani Therapeutics For further details see: Rani Therapeuti...

2023-12-01 10:20:04 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Rani Therapeutics GAAP EPS of -$0.36 misses by $0.05 Canaccord believes Rani restructuring will help speed development For further details see: ...

2023-11-09 13:33:11 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Canaccord believes Rani restructuring will help speed development Rani to cut 25% of workforce as it reprioritizes drug programs Seeking Alphaȁ...

Rani Therapeutics Holdings Inc. (RANI) is expected to report $-0.47 for Q3 2023